APRI - Apricus Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Apricus Biosciences, Inc.

11975 El Camino Real
Suite 300
San Diego, CA 92130
United States
858-222-8041
http://www.apricusbio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees11

Key Executives

NameTitlePayExercisedYear Born
Mr. Richard W. PascoeCEO, CFO, Sec., Principal Accounting Officer & Director500.23kN/A1964
Mr. Neil C. MortonSr. VP & Chief Bus. Officer286.81kN/A1976
Mr. Brian T. DorseyConsultant331.89kN/A1969
Ms. Kelly DeckExec. Director of Fin.N/AN/AN/A
Ms. Mary NaggsVP & Gen. CounselN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma. It has a license and stock issuance agreement with Forendo Pharma Ltd. to develop and commercialize fispemifene, a tissue-specific selective estrogen receptor modulator to treat symptomatic secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men. Apricus Biosciences, Inc. operates in Europe, Canada, Latin America, and the Asia Pacific. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.

Corporate Governance

Apricus Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.